Gilead Sciences (GILD) stock
NASDAQ
As of the Nov 5, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $207.8B
- As of Nov 5, 2026
- P/E
- -53.80x
- Trailing twelve months
- P/B
- 15.94x
- Latest reported equity
- P/S
- 6.71x
- Trailing twelve months
- ROE
- -29.6%
- Trailing twelve months
- Dividend yield
- 1.89%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $207.8B
- As of Nov 5, 2026
- P/E
- -53.80x
- Trailing twelve months
- P/B
- 15.94x
- Latest reported equity
- P/S
- 6.71x
- Trailing twelve months
- ROE
- -29.6%
- Trailing twelve months
- Dividend yield
- 1.89%
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-53.80x
Net loss — not comparable
P/B
15.94x
P/S
6.71x
Earnings and dividend metrics▾
Earnings
EPS
-$3.12
Earnings per share
BPS
$10.52
Book value per share
ROE
-29.6%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $3.12 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $10.52 of net assets.
- ROE — shareholder equity shrank by 29.6% over a year.
Dividends
Yield
1.89%
Dividend per share
$3.16
Payout ratio
-103.6%
Consecutive years
1+ yrs
Yield uses fiscal 2025 dividends · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about $316.00 before tax.
- Payout ratio — -103.6% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 1 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 6.8% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $7.77B+6.8%
$7.55B
Jul–Sep '24
$7.77B
Jul–Sep '25
$8.3B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 30, 2026.
- Earnings per share decreased 20.2% from the same quarter a year earlier.
- Revenue increased 6.8% from the same quarter a year earlier.
- Operating income increased 4.1% from the same quarter a year earlier.
- Net income decreased 20.4% from the same quarter a year earlier.
Filed Oct 30, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- O'Day Daniel PatrickChairman & CEO · Nov 2, 2026Open-market sale15,000 shares · $2.5MAvg. price $169.7402
Show 5 price lots
- 7,796 shares × $170.3527$1.3M
- 2,000 shares × $171.0627$342K
- 1,904 shares × $169.2733$322K
- 1,700 shares × $168.1006$286K
- 1,600 shares × $167.3999$268K
- O'Day Daniel PatrickChairman & CEO · Oct 30, 2026Open-market sale15,881 shares · $2.8MAvg. price $175.2456566,683 shares held after
- O'Day Daniel PatrickChairman & CEO · Oct 30, 2026Option exercise15,881 shares · $1.1MAvg. price $72.34582,564 shares held after
- Mercier JohannaChief Comm & Corp Aff Officer · Oct 15, 2026Open-market sale3,000 shares · $469KAvg. price $156.22113,684 shares held after
- Dickinson Andrew DChief Financial Officer · Oct 15, 2026Open-market sale3,000 shares · $469KAvg. price $156.22161,096 shares held after
- O'Day Daniel PatrickChairman & CEO · Oct 1, 2026Open-market sale15,000 shares · $2.2MAvg. price $147.9005
Show 2 price lots
- 12,000 shares × $147.719$1.8M
- 3,000 shares × $148.6265$446K
- Burkhart ErinSVP, Controllership · Sep 22, 2026Shares withheld for taxes768 shares · $117KAvg. price $152.671,455 shares held after
- Burkhart ErinSVP, Controllership · Sep 22, 2026Option exercise2,223 shares2,223 shares held after
- Dickinson Andrew DChief Financial Officer · Sep 15, 2026Open-market sale3,000 shares · $436KAvg. price $145.29164,096 shares held after
- Mercier JohannaChief Comm & Corp Aff Officer · Sep 15, 2026Open-market sale3,000 shares · $433KAvg. price $144.2154
Show 3 price lots
- 1,600 shares × $143.6917$230K
- 800 shares × $144.4569$116K
- 600 shares × $145.29$87K
- O'Day Daniel PatrickChairman & CEO · Sep 10, 2026Shares withheld for taxes4,230 shares · $613KAvg. price $144.81581,683 shares held after
- Dickinson Andrew DChief Financial Officer · Sep 10, 2026Shares withheld for taxes1,347 shares · $195KAvg. price $144.81167,096 shares held after
- Mercier JohannaChief Comm & Corp Aff Officer · Sep 10, 2026Shares withheld for taxes1,347 shares · $195KAvg. price $144.81119,684 shares held after
- Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp · Sep 10, 2026Shares withheld for taxes285 shares · $41KAvg. price $144.818,759 shares held after
- Berger DietmarChief Medical Officer · Sep 10, 2026Shares withheld for taxes263 shares · $38KAvg. price $144.8119,522 shares held after
- Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp · Sep 10, 2026Option exercise590 shares9,044 shares held after
- Mercier JohannaChief Comm & Corp Aff Officer · Sep 10, 2026Option exercise2,797 shares121,031 shares held after
- Berger DietmarChief Medical Officer · Sep 10, 2026Option exercise533 shares19,785 shares held after
- O'Day Daniel PatrickChairman & CEO · Sep 10, 2026Option exercise8,780 shares585,913 shares held after
- Dickinson Andrew DChief Financial Officer · Sep 10, 2026Option exercise2,797 shares168,443 shares held after
- O'Day Daniel PatrickChairman & CEO · Sep 1, 2026Open-market sale15,000 shares · $2.2MAvg. price $148.6395
Show 3 price lots
- 7,992 shares × $148.3636$1.2M
- 5,408 shares × $149.3817$808K
- 1,600 shares × $147.5087$236K
- WELTERS ANTHONYDirector · Aug 26, 2026Open-market sale18,000 shares · $2.7MAvg. price $148.6233
Show 4 price lots
- 6,880 shares × $148.8227$1.0M
- 4,600 shares × $148.824$685K
- 3,402 shares × $148.2353$504K
- 3,118 shares × $148.3106$462K
- WELTERS ANTHONYDirector · Aug 26, 2026Option exercise18,000 shares · $1.1MAvg. price $61.0584
Show 2 price lots
- 10,282 shares × $61.35$631K
- 7,718 shares × $60.67$468K
- Bluestone JeffreyDirector · Aug 20, 2026Open-market sale4,974 shares · $721KAvg. price $145.008510,066 shares held after
Show 4 price lots
- 1,816 shares × $144.9248$263K
- 1,658 shares × $145.7286$242K
- 1,165 shares × $143.7543$167K
- 335 shares × $146.26$49K
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QThe company said its total revenues increased 7% to $8.3 billion and $23.1 billion for the 3 and 9 months ended September 30, 2026, respectively, compared with the same periods a year earlier. It cited higher sales of HIV products, Trodelvy and Livdelzi as the main drivers.Published Oct 30, 2026 · Filed Oct 30, 2026Read the summary →
- AI summary8-KGilead said its product sales for Q3 2026 rose 13% from a year earlier to $8.3 billion, and that excluding Veklury, they rose 16% to $8.2 billion. The company cited higher sales of HIV products, Trodelvy and Livdelzi as the main drivers.Published Oct 29, 2026 · Filed Oct 29, 2026Read the summary →
- AI summary8-KGilead Sciences said that on Q2 2026 total revenues were $7.8 billion, up 10% year-over-year, and diluted loss per share was $(8.45), compared with diluted earnings per share of $1.56 in the same period in the prior year. The company cited the $(9.08) per share impact of acquired in-process research and development expenses as the primary driver of the loss per share.Published Oct 2, 2026 · Filed Aug 4, 2026Read the summary →
- The company said its total revenues increased 7% to $8.3 billion and $23.1 billion for the 3 and 9 months ended September 30, 2026, respectively, compared with the same periods a year earlier. It cited higher sales of HIV products, Trodelvy and Livdelzi as the main drivers.Read the full analysis →
- Gilead said its product sales for Q3 2026 rose 13% from a year earlier to $8.3 billion, and that excluding Veklury, they rose 16% to $8.2 billion. The company cited higher sales of HIV products, Trodelvy and Livdelzi as the main drivers.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Gilead Sciences (GILD) stock information
NASDAQ
Gilead Sciences (GILD) is listed on NASDAQ. Its market capitalization is about $207.8B. On trailing-twelve-month earnings the P/E ratio is -53.8, and the P/B ratio is 15.94. Return on equity is -29.6%. These figures are computed in-house from official filings and are reference information only.
Gilead Sciences — frequently asked questions
- What is the P/E ratio of Gilead Sciences (GILD)?
- On a trailing-twelve-month basis, GILD trades at a P/E ratio of -53.8. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Gilead Sciences?
- GILD has a market capitalization of about $207.8B. The figure moves with the share price and is refreshed each trading day.
- Does Gilead Sciences pay a dividend?
- GILD has a dividend yield of about 1.89%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.